Australia's drug regulator says a vial sold as retatrutide contained eight times the usual semaglutide dose

Australia's Therapeutic Goods Administration says a vial sold as the experimental weight-loss drug retatrutide held none of that drug. Laboratory testing instead detected semaglutide, the molecule in the approved medicines Ozempic, Wegovy and Rybelsus, at about eight times the concentration measured in semaglutide products on the Australian Register of Therapeutic Goods ^[1]. The person who used it vomited without letup, tore an esophagus and was treated at a hospital ^[1].

The alert went out on Monday, September 14, 2026, after the agency received a report of a serious adverse reaction ^[1]. The vial tested came in its original unmarked packaging ^[1]. The TGA's alert document carries a date of September 13 ^[1].

Retatrutide has not been cleared by the TGA or, the agency said, by any comparable regulator overseas; it remains under study in human clinical trials, which means anything sold under that name outside a trial may be counterfeit and should not be used ^[1]. The BBC reported that no regulatory body has approved the drug for human use ^[2].

"The biggest risks with unapproved peptide products are not knowing what is in the vial, how much of or even what substance it contains, whether it is sterile, or whether it contains other contaminants or toxins," said Professor Robyn Langham AM, the TGA's Chief Medical Adviser ^[1]. Professor Anthony Lawler, who heads the agency, said the case underlines the difference between medicines approved for supply in Australia and imported goods, which do not pass through the same safety and quality checks ^[1].

Investigators are still trying to work out where the vial came from and to pull such products off the market; the origin had not been established when the alert was posted ^[1]. Individuals face civil penalties of up to A$1.82 million per breach, corporations up to A$18.2 million, and criminal penalties reaching seven years in prison. The TGA added unapproved peptide products to its priority focus areas in June ^[1].

Dr Terri-Lynne South, who chairs RACGP Specific Interests Obesity, told the medical publication newsGP that the size of the dose is "really worrisome from a safety point of view" and that earlier warnings are not getting through. General practitioners, she said, should ask open, non-judgemental questions about over-the-counter and complementary products so that patients feel able to say they have used peptides ^[1].

The problem is not confined to Australia. The BBC found vials marketed as "reta" for sale in British gyms, nail and beauty salons, hairdressers and on social media, and reported that the UK's Medicines and Healthcare Products Regulatory Agency seized more than 2,000 unlicensed retatrutide pens in a raid on an illegal weight-loss drug factory in Northampton last year ^[2]. Tom Davies, a 20-year-old from Brighton, told the BBC he gave himself eight times the recommended dose from a vial bought through a Chinese supplier and spent 72 hours with diarrhea and nausea ^[2]. Endocrinologist Donal O'Shea said young, fit patients are turning up at hospitals with nausea, vomiting, diarrhea and in some cases kidney failure ^[2].

Eli Lilly, which has been developing retatrutide for nearly a decade, says on its website that nobody should take anything claiming to be retatrutide outside a Lilly-sponsored clinical trial, and warns that illicit versions may carry unknown ingredients or contaminants, or too much, too little or the wrong active ingredient ^[2]. The company says it has reported more than 14,000 websites, advertisements and social media posts for allegedly marketing the drug illegally ^[2].

Retatrutide is designed to act on three hormone targets — GLP-1, GIP and glucagon — where semaglutide works on one and tirzepatide on two ^[2].

Why it matters for patients

For anyone weighing an unapproved injectable, the Australian case shows the contents cannot be judged from the label. In this instance the buyer received a medicine that is legally sold in the US, semaglutide, but at roughly eight times the strength of the approved semaglutide products the TGA has assessed — a dose nobody chose ^[1]. The consequences included an esophageal tear and hospital care ^[1].

In the US, semaglutide is available as Ozempic, Wegovy and Rybelsus, and tirzepatide as Mounjaro and Zepbound; those products have set doses and manufacturing oversight. Retatrutide has no approval in the US or anywhere else ^[2]. Clinicians in both countries said patients often keep black-market use to themselves, and that asking without judgment makes disclosure more likely ^[1][2].

What happens next

Lilly intends to file for US Food and Drug Administration approval of retatrutide in early 2027, and the BBC reported that a review can take up to a year, which would put the earliest legal US sales at the end of 2027. If the MHRA approves, UK sales could follow in 2028 ^[2].

The BBC reported that about half of drugs at this stage of testing eventually win FDA approval ^[2]. The TGA has not named a source for the Australian vial, and no connection between that case and the British products has been reported ^[1][2]. Whether the Australian patient recovered fully has not been disclosed ^[1].